Navigation Links
Moffitt Cancer Center: Growing interest in prognostic test for non-small cell lung cancer
Date:4/26/2010

Tampa, FL (April 23, 2010) Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy. The correlation between ERCC1 levels and therapy response was discovered at Moffitt Cancer Center and exclusively licensed to Genzyme Corporation in November of 2007. Genzyme Genetics, a business unit of Genzyme Corporation, officially launched the ERCC1 Analysis on May 1, 2009.

Several studies1-6 have shown that evaluating the expression levels of excision repair cross-complementation group 1 (ERCC1) may help physicians identify patients that may benefit from platinum-based chemotherapy - currently considered the standard of care in advanced NSCLC. Specifically, low expression levels of ERCC1 have been related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.

"We are very pleased that many medical oncologists have begun utilizing this lung cancer test to better identify chemotherapy for non small cell lung cancer patients," said Jarett Rieger, Director of the Office of Technology Management and Licensing at Moffitt. "This test is an example of personalized medicine emanating from Moffitt Cancer Center, and as a result of our licensing partnership with Genyzme this test can now benefit lung cancer patients."

"The ERCC1 test complements our growing menu of personalized tests that predict response to treatment in NSCLC, said Celeste Chenet-Monte, Director Marketing, Oncology at Genzyme Genetics. "Other tests on our menu include EGFR and KRAS mutation analysis, ALK gene rearrangements and EGFR amplification, all of which can be used for prediction of response to targeted therapies used to treat patients with ad
'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
2. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
3. A study by the MUHC and McGill University opens a new door to understanding cancer
4. ESF EURYI award winner aims to stop cancer cells reading their own DNA
5. Protein chatter linked to cancer activation
6. Newly created cancer stem cells could aid breast cancer research
7. Western diet linked to increased risk of colon cancer recurrence
8. Obesity and lack of exercise could enhance the risk of pancreatic cancer
9. Low levels of key protein may indicate pancreatic cancer risk
10. Birth records hold pancreatic cancer clue
11. Many parents at-risk for cancer disclose genetic test results to children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... PRINCETON, N.J. , June 25, 2015  TAKE ... awarded a patent by the United States Patent and ... Data Standardization". This process leverages TAKE Solutions, Clinical Accelerators ... by over 50% (when compared to standardization without the ... At the heart ...
(Date:6/24/2015)... MARTIGNY, Switzerland , June 24, 2015 /PRNewswire/ ... strategic partnership with emerging biometric password solution one ... http://photos.prnewswire.com/prnh/20150623/225014LOGO one face in, ... offers a ground-breaking and affordable multifactor-authentication biometric answer ... speaker recognition technology, provided in partnership with KeyLemon, ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... world would help stave off an imminent global extinction ... Proceedings of the National Academy of Sciences ( www.pnas.org ... member organizations of the Alliance for Zero Extinction (AZE ... with imminent extinction, each of which is in need ...
... has its roots in yielding more food to feed more ... , His team's study appears in ... , The team made tomato plants over-express the gene, ... resulted in roots making better use of limited water, said ...
... and the National Human Genome Research Institute (NHGRI), ... (NIH), today launched a comprehensive effort to accelerate ... through the application of genome analysis technologies, especially ... Cancer Genome Atlas (TCGA), will begin with a ...
Cached Biology News:Pretreating rogue cancer cells with aspirin cripples their resistance to targeted therapy 2Anyway you slice it, tomatoes cut through drought with new gene 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
(Date:6/29/2015)... 30, 2015   Pharnext SAS today announced that ... the treatment of Charcot-Marie-Tooth Type 1A (CMT1A), is being presented ... Peripheral Nerve Society (PNS) Biennial Meeting at the Quebec Congress ... 27 - July 2, 2015. At Poster Viewing ... 1, 5p.m. to 7p.m. EDT: Poster 23: ...
(Date:6/29/2015)... ... June 29, 2015 , ... The global microfluidics market is ... period (2015 to 2020). The market is mainly driven by the rising geriatric ... R&D. However, lack of adequate healthcare and research infrastructure in emerging markets, dearth ...
(Date:6/29/2015)... WASHINGTON , June 29, 2015  AACC, ... to better health through laboratory medicine, is pleased ... journal, Clinical Chemistry , has increased to ... Reports. This increase places Clinical Chemistry ... and reflects the significant influence of the research ...
Breaking Biology Technology:Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 2Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 3Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 4Microfluidics Market Growing at 19.3% CAGR To 2020 – New research available at ReportsnReports.com 5AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3
... scientists at the National Institute of Standards and ... highly efficient piezoelectric material into a silicon microelectromechanical ... advances in sensing, imaging and energy harvesting. ... when fed electricity and, conversely, generates an electric ...
... Modern Mobility Aids, Inc. (OTCBB: MDRM) (the "Company") ... financing required to execute its closing agreement to acquire ... ("LumiGene"). Modern Mobility Aids, Inc. is a ... and development in the Bio-Pharma sector as well as ...
... The question of how many polyhedral nanocrystals of silver ... burning on many lips but the answer holds importance ... plasmonics! Researchers with the U.S. Department of Energy (DOE),s ... the door to a simpler approach for the fabrication ...
Cached Biology Technology:Tiny levers, big moves in piezoelectric sensors 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 2Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies 3On the road to plasmonics with silver polyhedral nanocrystals 2On the road to plasmonics with silver polyhedral nanocrystals 3
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
Mouse monoclonal antibody to FMN2 - formin 2...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Mouse monoclonal [CAT-2] to Chloramphenicol Acetyltransferase...
Biology Products: